FRAMEWORK FOR SYSTEMATIC IDENTIFICATION OF ETHICAL ASPECTS OF HEALTHCARE TECHNOLOGIES: THE SBU APPROACH

Emelie Heintz
Swedish Council on Health Technology Assessment (SBU); Center for Medical Technology Assessment (CMT), Department of Medical and Health Sciences, Linköping University
emelie.heintz@sbu.se

Laura Lintamo
Swedish Council on Health Technology Assessment (SBU)

Monica Hulcrantz, Stella Jacobson
Swedish Council on Health Technology Assessment (SBU); Department of Learning, Informatics, Management and Ethics (LIME), Karolinska Institutet

Ragnar Levi
Swedish Council on Health Technology Assessment (SBU)

Christian Munthe
Department of Philosophy, Linguistics and Theory of Science, University of Gothenburg
Sofia Tranæus
Swedish Council on Health Technology Assessment (SBU); Faculty of Odontology, Malmö University; Department of Dental Medicine, Karolinska Institutet
Pernilla Östlund
Swedish Council on Health Technology Assessment (SBU); Faculty of Odontology, Malmö University
Lars Sandman
School of Health Sciences, University of Borås; National Centre for Priority Setting in Health Care, Linköping University

Objectives: Assessment of ethical aspects of a technology is an important component of health technology assessment (HTA). Nevertheless, how the implementation of ethical assessment in HTA is to be organized and adapted to specific regulatory and organizational settings remains unclear. The objective of this study is to present a framework for systematic identification of ethical aspects of health technologies. Furthermore, the process of developing and adapting the framework to a specific setting is described.

Methods: The framework was developed based on an inventory of existing approaches to identification and assessment of ethical aspects in HTA. In addition, the framework was adapted to the Swedish legal and organizational healthcare context, to the role of the HTA agency and to the use of non-ethicists. The framework was reviewed by a group of ethicists working in the field as well as by a wider set of interested parties including industry, interest groups, and other potential users.

Results: The framework consists of twelve items with sub-questions, short explanations, and a concluding overall summary. The items are organized into four different themes: the effects of the intervention on health, its compatibility with ethical norms, structural factors with ethical implications, and long term ethical consequences of using the intervention.

Conclusions: In this study, a framework for identifying ethical aspects of health technologies is proposed. The general considerations and methodological approach to this venture will hopefully inspire and present important insights to organizations in other national contexts interested in making similar adaptations.

Keywords: Ethics, Guideline, Framework, Procedure, Health technology assessment

The authors thank the following for their constructive comments that greatly contributed to the final version of the framework presented in this study: colleagues, members of the Board, the Scientific Advisory Committee, and the Alert Advisory Board at SBU – Swedish Council on Health Technology Assessment; Assoc. Prof. Gert Helgesson (Department of Learning, Informatics, Management and Ethics (LIME), Karolinska Institutet); Prof. em. Göran Hermerén (Department of Medical Ethics at Lund University); Prof. Bjorn Hofmann (University College of Gjovik, and Centre for Medical Ethics, University of Oslo Norway); Prof. Nils-Eric Sahlin (Department of Medical Ethics at Lund University); Dr. Gustav Tinghög (National Centre for Priority Setting in Health Care, Linköping University); and Dr. Mia Svantesson (Centre for Health Care Sciences, Örebro University Hospital). The authors also thank the representatives from the following organizations for their contribution to the final version of the framework: Centre for Health Care Sciences, Örebro University Hospital; The Dental and Pharmaceutical Benefits Agency in Sweden (TLV); LIF — the research-based pharmaceutical industry in Sweden; Medtronic (The HTA-unit of the Stockholm County Council); Medical Products Agency — Sweden; Public Health Agency of Sweden; Swedish Medtech (The Association for Medical Technology in Sweden); The Swedish Association of Health Professionals; The Swedish Association of Local Authorities and Regions (SALAR); The Swedish Association of Physiotherapists; The Swedish Medical Association; The Swedish National Council on Medical Ethics (SNER); and The Swedish Society of Nursing. We are also grateful to the two anonymous reviewers for useful and helpful comments on the draft of this manuscript.

Health care is founded on and permeated by ethical values and norms. Hence, all use of health technology is likely to raise ethical issues of some kind. To guide decisions on the use or non-use of specific health technologies, health technology assessment (HTA) is a tool for assessing technologies from a medical, economic, social, legal, and ethical perspective (1). Hofmann’s checklist of thirty-three ethics questions provided a starting point for systematic integration of ethics into HTA (2) and laid a basis for developing similar sets of questions at both national and international levels (e.g., Burls et al., 2011 [3],...
Saarni et al., 2011 [4], and Assasi et al., 2014 [5]). Nevertheless, how the implementation of ethical assessment in HTA is to be organized remains unclear. The existing sets of questions are also of a general nature and may need to be adjusted for use in specific regulative and organizational settings (6).

Ethical aspects are included as a vital part of the HTA reports produced by The Swedish Council on Health Technology Assessment (SBU). The assessments of ethical aspects have been based on well-established areas of concern in healthcare ethics, such as the four basic principles of medical ethics: beneficence, non-maleficence, respect for autonomy and justice (7,8). Existing checklists (2;9;10) and models (11) have also been used. However, there has been a demand for a common framework that could guide the ethical assessments in all of the HTA projects at SBU. There has also been a demand for a framework for ethical assessment adapted to effective health policy and regulation. Besides being of use at SBU, such a framework could be an important tool for other organizations or decision makers involved in quality assessment and priority-setting of Swedish health care. The need for such a common framework was emphasized in 2010 when the Swedish Health and Medical Services Act (HMSA) introduced a requirement that all new health technologies of potential importance for human value were emphasized in 2010 when the Swedish Health and Medical Services Act (HMSA) introduced a requirement that all new health technologies of potential importance for human value and integrity should be assessed in terms of “individual as well as social ethical aspects” (12). A follow-up in 2013, highlighted that the health care providers needed guidance on how to achieve such an implementation (13).

In this study, we present a framework for systematic identification of relevant ethical aspects of healthcare technologies. Furthermore, we describe the process of developing and adapting the framework to the specific setting in which it will be used. This work may be used by other organizations or inspire and inform others to conduct similar adaptations to their organizational or national settings.

METHODS

Developing the Framework

An attempt to form a context-specific framework was initially made by a regional HTA agency in Sweden (14), in which the checklist by Hoffmann (2005) was adapted to the principles of the Swedish ethical platform for healthcare priority-setting (see Figure 1) (15) and other relevant features of the Swedish health-care legislation. This pilot framework was well received and rendered support for the idea of developing a version for wider application. At the same time, it highlighted the need to consider further aspects and circumstances in the development of such a framework.

To develop such a framework for wider application, a group consisting of seven HTA experts at SBU and two ethicists (henceforth called the working group) was formed and met regularly from November 2012 to May 2014. The regional checklist acted as the starting point (14). In addition, the working group identified various aspects important to take into account when creating a framework for ethics in HTA that is adjusted to specific healthcare contexts (see next section).

To identify other possible checklists for identification of ethical aspects in HTA, Web sites of different HTA organizations were explored. The identified checklists (2;9;10) and their references were reviewed and compared with the regional framework, resulting in some questions being added. Swedish healthcare regulation was also analyzed more in-depth, leading to further revision of the content and the structure of the framework. The following aspects of Swedish healthcare legislation were incorporated into the framework: the goal of care in terms of health (HMSA), the principles of the Swedish ethical platform for priority setting (included in HMSA), autonomy (HMSA), and privacy (HMSA and Patient Data Act, PDA).

To validate the first draft of the framework, it was sent for review to six academic ethicists and one health economist with special training in ethics. The ethicists represented both theoretical and empirical research in the areas of medical ethics, practical philosophy and nursing science. Based on the feedback received, the framework was modified further. The comments helped to clarify the questions and reorganize the structure without essentially changing the content of the framework.

Further validation was performed through internal review at SBU, as well as through the involvement of other healthcare organizations, political bodies, interest groups, and parts of industry identified as potential stakeholders. These included the Swedish national council on medical ethics (SMER), the Swedish national parliament, national governmental representatives, regional HTA agencies, interest groups within the medical technology and pharmaceutical industry, insurance companies, and unions/other professional organizations. This further round of review resulted in thirty responses and led to additional revisions of the structure of the framework and clarifications of the text. These reviews did not affect the content matter of the framework.

Aspects to Consider when Adapting General Checklists to Specific Contexts

During the project, we identified four aspects to consider when developing a framework for ethics in HTA that is adjusted to specific healthcare contexts. These have all been taken into account in the development of the framework discussed in this study.

Stages of the HTA process: The more general checklists do not distinguish between specific stages of the HTA process. This can lead to problems with identifying the most relevant questions for each specific stage, for example, when prioritizing between proposed project, in the scope of projects or when assessing the technology.
**Human Value Principle**

All human beings are of equal value and have the same right independent of personal characteristics or function in society.

The principle determines primarily what factors that should not determine the priority setting, e.g. chronological age, social and economic situation, previous life-style etc. But it does allow these factors to be taken into account if they affect the effectiveness of the treatment, e.g. biological age and future life-style.

---

**Need and Solidarity Principle**

Resources should be distributed according to need.

When it is necessary to prioritise among effective interventions – more of health care’s resources should be given to those in greater need, meaning those with the most severe conditions, and those with the lowest quality of life. This applies even if it means that everyone cannot have their needs met in part or at all.

---

**Cost-effectiveness Principle**

In choosing between different interventions one needs to strive for a reasonable relationship between costs and effects, measured in terms of improved health and quality of life.

The relationship between the Need and Solidarity Principle and the Cost-effectiveness Principle is such that patients with severe diseases and substantially impaired quality of life should take precedence over milder cases, even if this care involves “substantially” greater costs for a given health benefit.

---

**RESULTS**

Three different versions of the ethics framework were considered necessary: one for prioritization and scoping of HTA projects, one for identification of ethical aspects of the specific technologies being assessed, and finally, one for prioritization of research questions. In this study, only the framework for identification of ethical aspects when assessing health technologies is presented. This section begins with a description of this framework. Next, specific adaptations of this framework to healthcare legislation, and organization of the healthcare system, as well as available ethical competence, are described. Finally, a process for using the framework is proposed.

**Outline of the Framework’s Content and Structure**

The framework consists of twelve items with sub-questions and short explanations (see Figure 2 for an overview, and Figure 3 for an example of one of the items), as well as an overall concluding summary. The items are organized into four different themes: the effects of the intervention on health, its...
compatibility with ethical norms, structural factors with ethical implications, and long-term ethical consequences of using the intervention. The structural order of the questions, illustrated by the figure below, reflects an argumentative priority of the items.

The first theme concerns the intervention’s effect on patient health, including whether there are ethical or methodological problems in substantiating that effect, the severity of the condition, as well as health effects on third parties. If a technology exhibits no, too weak, or too badly substantiated positive benefits over risk ratio, there is no need to consider the other themes to be able to conclude that the technology should not be used. If the technology is currently being used, this ratio will form an important background for the assessment of the other themes of the framework. The final assessment within this theme relates to the balance between benefits and harms given the aim of the health technology, the urgency of the intervention, given the severity of the condition, and to what extent lack of evidence due to ethical or methodological factors may be tolerated.

The next theme, compatibility with ethical norms, covers aspects of equality and justice, autonomy, privacy, and cost-effectiveness. If any of these are violated to an unacceptable degree, further pondering of the other themes will not be able to change the fact that the technology is unacceptable. If it has some ethical downsides of less serious kinds, these will form an important background to the assessment within the subsequent themes.

The theme on structural factors contains questions on how resources, organizations, professional values and roles, as well as stakeholder interests, affect equal access to health care. The theme on long-term ethical consequences complements the others to ensure a more inclusive scope than immediate clinical or societal concerns.

The final item is a summary of all of the ethical aspects raised by the technology. This summary is not by itself a conclusion. Instead, it is thought to describe issues to ponder further, arguments for and against the use or the implementation of the technology, as well as suggested modifications of the
Question 5 – Equality and justice: Is there a risk that access to the intervention violates the principle of human value or current legislation against discrimination?

According to the ethical platform’s human value principle, provision of health care shall not be based on consideration of personal characteristics or a person’s position in society, unless these have a clear association with the severity of a condition or the effect of an intervention. In the Health and Medical Services Act (HMSA), this is expressed partly in that the aim is to provide care on equal grounds and partly in that care shall be provided with respect for the concept of all people being of equal value and for the dignity of the individual. This is also supported by Swedish legislation against discrimination.

Is there a risk that access to care is influenced by those factors, which the principle of human value and legislation against discrimination specify should not determine access to care and treatment? The ethical platform specifies these factors as a person’s gender, chronological age, social and financial status, earlier lifestyle, education or the ability to safeguard their own interests. The legislation against discrimination also lists transgender identity or expression, ethnicity, religion or other belief, physical disability and sexual orientation.

Examples of questions:

- Does the intervention require a well-ordered social situation or well-developed social support to function? Are groups who lack such support disadvantaged?
- Is the intervention associated with co-payment by the patient? Is there a risk that this will disadvantage certain groups?
- Is there a risk that the lack of evidence for an intervention’s effect in certain groups (e.g. groups based on age, gender, ethnicity, sexual orientation etc) will mean that these groups will not have access to the intervention, despite transferable evidence from other similar groups?
- Is assessment of the cost-effectiveness of the intervention influenced by whether the patient group is an active part of the work force?
- Does the intervention require the patient or a third party to assume some responsibility for self-care, which for some patients may be difficult to manage, thus leading to unequal access to the intervention?

In the Swedish society, the standpoint on equality of treatment is generally given a broad interpretation: that people should have equal opportunity to function and achieve a generally good quality of life in society. Nor should our attitude to human dignity be influenced by personal characteristics or position in society. Can the intervention influence the perception of the patient or other people with respect to the patient’s value in society? The following are some examples of questions to aid such an assessment:

- Does the intervention affect the person’s appearance, or ability to contribute to society through work or other activity, in such a way that the intervention can be regarded as belittling or stigmatising in the long term?
- Can the patient group or other groups in society form the opinion that implementation of the intervention will have a negative influence on their ability to achieve equality, the attitude to their equal worth or their perception of themselves as worthwhile citizens?
- Are there similar interventions which are in use and accepted in society, which can thus give some guidance as to whether or not this intervention should be implemented?

Figure 3 Example of a question in the framework for identification of ethical aspects for assessment of health technologies.

A Proposed Process for Using the Framework

Successful use of the framework requires integration with a specific working process that suits the existing administrative circumstances and the jurisdictional context. This is necessary
to maximize the usefulness of the framework for specific HTA agencies and healthcare decision makers. It is also necessary to identify a proper place and form for involving ethical expertise in HTAs (16). Here, we present an example of how the framework may be used in a HTA process by using the case of SBU.

First, the project group is recommended to start to reflect on potential ethical aspects of the assessed technology without the use of the framework (at SBU the project group consists of internal staff members and external field experts). This initial “brain-storming” exercise is done to not direct the focus of attention away from issues that spontaneously are viewed as ethically challenging within the field. The brainstorming exercise is led by the project director, but the group members are basically free to voice any ethical problems that they associate with the technology. The result is documented and later assessed in relation to the outcome of the more systematic approach using the framework. Second, the project group systematically uses the framework to identify further possible ethical challenges. A possible consequence of these two steps is the need to modify the scope of the project, which could lead to further literature searches on the topic as whole, or on specific ethical issues (17). Third, as the assessment of the scientific evidence proceeds, with the possible addition of new search results, the project group may need to return to the framework for further reflection on whether the evidence modifies or deepens the initial ethical assessment. If more substantial and difficult ethical issues are identified during this process, the project group is recommended to consult professional ethics expertise for support or for a more full-fledged ethical analysis of the assessed technology. At this point, a systematic approach for such expert involvement has not yet been formally developed at SBU. However, the group is recommended to liaise with a government advisory body on medical ethics (The Swedish National Council on Medical Ethics) if the technology raises, what appears to be new ethical issues, or issues of general importance from a societal perspective. Thus, the decision concerning the involvement of ethical expertise is currently in the hands of the ones conducting the HTA. Finally, the result of the assessment is summarized as a list of ethical pros and cons of the technology. This is done even if some of the themes on the list rules out the intervention, as there is always a need to clarify the entire argumentative situation, in case other parties assess it differently.

**DISCUSSION**

We have presented the process and the main results of the development of a framework for identifying ethical aspects in the assessment of health technologies. This framework will be used by SBU, but other Swedish healthcare organizations have also shown an interest. The framework meets the need of a systematic approach to identify ethical aspects for further analysis in the context of HTA. In Sweden, this need has recently been emphasized by a legal requirement on ethical assessment of all new healthcare technologies (12), resulting in healthcare providers requesting guidance on how to perform such assessment (13). The study describes how the framework has been adapted to suit the specific context of HTA and Swedish health care. In this adaptation, several factors to bear in mind when adapting and complementing previously available checklists to specific contexts have been identified. Hopefully, other jurisdictions and healthcare policy contexts beside HTA can learn from this process and its outcome.

In particular, the framework as a whole possesses four specific qualities:

(i) The presented framework is adapted to one specific part of the HTA process, that is, the actual assessment of technologies. However, because ethical queries are raised in other parts of the process, for example, prioritization of project proposals or prioritization of research proposals to fill established knowledge gaps, this framework will be part of a more comprehensive set of frameworks. This allows for a refinement of the ethical questions needed to be raised at each specific stage that would not be available with only one framework for the entire HTA process.

(ii) As the framework has been developed for identifying ethical aspects of the assessed technology, and not to perform a full-fledged ethical analysis, it may also serve as a tool for the project group to decide if and when further expertise in ethics needs to be consulted. It may further serve as a bridge between the views of the project group and the involved ethical expertise concerning the role of ethics in HTA.

(iii) It is structured into a logical order of argumentative priority, emphasizing more clearly than existing checklists how the questions are linked to each other and how the answers to some of the questions depend upon the answers to previous questions (see Figure 2).

(iv) It has been adapted to the specific jurisdictional and healthcare policy context as well as to the HTA process. Hence, the framework provides both guidance and consistency in how to approach ethical assessment in relation to current laws and regulations of the context.

Reviewers consulted in the process of designing the framework agreed that it captures the ethical standpoints to address in Swedish health care, although some of them remarked that some questions go beyond strictly clinical ethics, that is, ethical problems arising in the context of interacting with patients. Furthermore, some of the reviewers did not consider questions about relevant effects of the technology as strictly ethical. However, we would argue that these aspects clearly relate to important ethical norms in form of beneficence etc. This is a consequence of the attempt to capture both core clinical ethical values and norms, as well as what Hofmann refers to as process, social or interactive aspects of the technology, linked to overall effects of its use in a specific social context (18).

Some of the consulted ethicists raised concerns that the framework might trivialize the complexity of ethical analysis. Although understandable, such criticism overlooks the fact that the framework is not itself a vehicle for solving ethical issues, only for identifying and clarifying them. Besides the questions and their argumentative priorities, the framework is also presented together with a proposed process for its use, including
the possibility to consult ethical expertise to assist with more in-depth analysis when needed. Of course, this suggests that users need to have sufficient knowledge of ethical assessment to be able to identify when the complexity of ethical issues require consultancy of professional ethicists. This further accentuates the need for sufficiently strong organizational support, in the form of appropriate education for professionals using the framework. In addition, any use of the framework should be associated with a clarified working process. The organization needs to specify when and how the matter of possible involvement of ethics expertise is to be raised. Finally, the proposed process of how to use the framework prescribes an open-ended start, where ethical aspects are pondered upon independently of the actual list of structured questions.

Another concern has been that the ethical assessment results in a recommendation, while the role of SBU as a HTA agency is to make an objective assessment that is directed to decision makers. Indeed, it may be difficult to draw a strict line between assessment and appraisal when it comes to normative issues (19). However, this has been taken into account by not requiring that the ethical assessment leads to a strict conclusion on whether the considered intervention is ethically acceptable or not. This suggests that the ethical assessment cannot (without qualification) be used to decide on coverage or not or whether it should be recommended or banned, etc. Rather, the result of the assessment is summarized as an informative list of pros and cons of the technology from the different ethical perspectives compatible with Swedish healthcare legislation, and it is up to the decision makers to draw a conclusion based on this information. At the same time, this opens up for a possible problem for decision makers. If lacking ethics training, it may be difficult to assess the importance of the ethics analysis in the bulk of information that they are to base their decisions upon.

CONCLUSIONS
This study presents a framework for identifying ethical aspects of health technologies. It also illustrates how specific regulations and contexts may suggest special adaptations and variations to such a framework and the process for its use. In particular, the framework includes a wider set of issues than traditional clinical ethical concerns, otherwise at the center of healthcare ethics discourse. The general considerations and methodological approach to this venture will, we hope, inspire organizations in other national contexts that are interested in making similar adaptations and provide important insights that might inform this work.

CONFLICTS OF INTEREST
The authors have no conflicts of interest to declare.

REFERENCES
The authors have no conflicts of interest to declare.


